Abstract:
myelogenous leukemia (Ph+CML) and several other malignancies (40, 43, 46) . In 82 addition to well-known anti-cancer effects, imatinib has demonstrated therapeutic 83 potential as an anti-inflammatory and anti-fibrotic agent in experimental models (51, 61) .
84
Furthermore, a recent case report suggests that imatinib has protective effects against 85 vascular edema (1). In contrast to this case report, imatinib treatment frequently results
86
in side effects related to vascular leak, including peripheral, periorbital and bone edema 87 (18, 19, 38) . The mechanisms by which imatinib exerts these differential effects on 88 vascular permeability, as well as its effects on inflammation, remain largely unknown. In 89 the present study, we investigated the effects of imatinib in experimental murine models from multiple independent experiments were pooled at discrete time points (maximum 155 LPS effect) using custom designed Epool software and plotted as the mean ± sem.
156
Silencing of c-Abl and Arg. Reduction of Abl family kinase expression with siRNA was
RESULTS

190
Effects of imatinib on lung vascular leak in LPS and VILI murine models. A key event in
191 ALI development is endothelial barrier disruption, which results in vascular leakage and was determined as is another assay for pulmonary endothelial disruption. In this assay, 209 imatinib significantly reduced lung tissue albumin levels by 42% (p<0.05) in LPS-210 challenged mice compared to LPS alone ( Figure 1C) . In contrast, imatinib had no 211 protective effect in VILI-injured mice but rather caused a 22% increase in lung tissue 212 albumin compared to the untreated VILI group that trended toward significance (p=0.18)
213
( Figure 1D ). These results demonstrate opposing effects of imatinib on lung 214 permeability in mice depending on the type of ALI insult.
215
Effects of imatinib on lung histopathology. We next examined lung tissue sections 216 stained with H&E in order to evaluate the effects of imatinib on the histopathological 217 changes induced by LPS (Figure 2A) or VILI ( Figure 2B ). Control groups (no LPS or 218 VILI) injected with vehicle or imatinib displayed normal lung histology without any inflammation. LPS-induced inflammatory cell infiltration, alveolar damage, and interstitial edema compared with the control group, and these histopathological markers of ALI 221 were reduced in imatinib treated mice (Figure 2A ). VILI induced a milder level of lung 222 injury than LPS, but the addition of imatinib substantially increased the observed 223 inflammatory cell infiltration, alveolar damage, and interstitial edema ( Figure 2B ).
224
Effects of imatinib on lung inflammation. To investigate the effects of imatinib on the 225 infiltration of inflammatory cells into the alveolar space, a characteristic of ALI/ARDS,
226
BAL total and differential cell counts were determined in mice injured by LPS or VILI.
227
Figures 2C and 2E demonstrate that LPS significantly increased BAL total cell counts 228 and neutrophils compared to the untreated group, while imatinib significantly reduced 229 this increase in total cells and neutrophils by 58.5% (p<0.01) and 64.5% (p<0.01)
230
respectively. In contrast, in the VILI model, imatinib significantly increased BAL total 231 cells by 39% (p<0.01) and trended toward increased neutrophils (Figures 2D and 2F) .
232
In addition, the levels of KC (mouse homolog of IL-8) and IL-6 in BAL were measured in 233 all experimental groups. Imatinib did not affect the basal levels of KC or IL-6 ( Figure 4C ).
260
Imatinib attenuates these LPS-induced alterations in VE-cadherin distribution and gap 261 formation (right lower panel in Figure 4C ). Another pathophysiologic characteristic of suggesting potential mechanisms by which it exerts its protective effects on ALI in LPS-273 challenged mice (Figures 1-3 ).
274
Effects of imatinib on mechanical CS-induced endothelial dysfunction. To explore the 275 effects of imatinib on the responses of lung EC to mechanical injury in vitro, a model of 276 pathologic 18% CS was used to mimic the injurious forces that are generated during 277 H TV MV and induce vascular barrier dysfunction (6). For these experiments, EC were 278 pretreated with imatinib and then exposed to 18% CS for 24 hrs. VE-cadherin expression levels in lung EC were decreased in a concentration-dependent manner by 280 imatinib after exposure to 18% CS ( Figure 5A and 5B). These results indicate that 20 281 µM imatinib decreased VE-cadherin expression by 25% (p<0.05) compared to control 282 while 40 µM imatinib produced a 58% decrease in CS-stimulated EC (p<0.001). To 283 confirm that imatinib induces a loss in VE-cadherin from EC junctions,
284
immunofluorescence staining for VE-cadherin was performed on CS-challenged cells.
285
The combination of 18% CS and imatinib resulted in a substantial loss of this critical 286 junctional protein at the periphery of the cells ( Figure 5C ). Prolonged exposure to 287 imatinib alone (20 µM, 24 hrs) had no effect on VE-cadherin distribution in static EC 288 ( Figure 5C ). In addition, imatinib alone (20 µM) did not alter VE-cadherin expression as 289 assessed by western blotting or EC barrier function as measured by ECIS (data not 290 shown). These data demonstrate that imatinib induces a barrier disruptive phenotype in 291 lung EC exposed to pathologic CS.
292
Effects of imatinib on cytokine production in EC after stimulation with LPS or 18% CS.
293
The release of pro-inflammatory cytokines after cell activation can further potentiate 294 lung injury. Given the effects of imatinib on BAL cytokine levels in mouse lungs ( Figure   295 3 and Table 1 ), we next determined the regulation of cytokine release by imatinib in 296 stimulated lung EC. HPAEC were pretreated with imatinib and exposed to LPS (1 µg/ml, Figure 6B ). This effect was not due to prolonged exposure to imatinib alone since IL-8 304 levels did not increase in static EC exposed to these concentrations of imatinib for 24 305 hrs (data not shown). Interestingly, this discrepant pattern was not replicated when IL-6 306 secretion was examined. IL-6 levels were significantly higher than control in EC 307 stimulated with LPS (1 µg/ml, 3 hrs) or 18% CS (24 hrs) by a factor of 7.9 (p<0.001) and 308 1.6 (p<0.001) respectively (Figures 6C and D) . However, imatinib inhibited IL-6 levels 
335
These intriguing observations suggest that imatinib may be a promising therapeutic 336 strategy for ALI syndromes. However, it has been reported that more than 50% of 337 patients who receive imatinib develop edema-related side effects (21, 26, 47) . Given (Figures 4D, 6 ).
362
These data are consistent with recent studies demonstrating inhibitory effects of 
